Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 14/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28633357 | 1.00 | LMNA (0.48) | LMNAUTS2RHDAC4NPC1RAB9A | |
| SCHEMBL23795925 | 0.90 | HDAC4 (0.53) | LMNAHDAC4NPC1RAB9A | |
| SCHEMBL23796124 | 0.90 | HDAC4 (0.53) | LMNAHDAC4NPC1RAB9A | |
| SCHEMBL23795923 | 0.90 | HDAC4 (0.53) | LMNAHDAC4NPC1RAB9A | |
| SCHEMBL23796438 | 0.90 | LMNA (0.47) | LMNAHDAC4NPC1RAB9AMTTP | |
| SCHEMBL28922738 | 0.90 | LMNA (0.47) | LMNAHDAC4NPC1RAB9AMTTP | |
| SCHEMBL28624302 | 0.90 | LMNA (0.47) | LMNAHDAC4NPC1RAB9AMTTP | |
| SCHEMBL28640207 | 0.88 | LMNA (0.45) | LMNAHDAC4NPC1RAB9AMTTP | |
| SCHEMBL23796399 | 0.88 | LMNA (0.45) | LMNAHDAC4NPC1RAB9AMTTP | |
| SCHEMBL28622798 | 0.88 | LMNA (0.45) | LMNAHDAC4NPC1RAB9AMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | LMNA 1925/4885UTS2R 2525/4885HDAC4 625/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | LMNA 1925/4885UTS2R 2525/4885HDAC4 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.